Genetic engineering in the post implantation uterus using a 4-hydroxytamoxifen regulated Cre recombination
Biology of Reproduction · 24.10.2026
DOI: 10.1093/biolre/ioag239 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biology of Reproduction, online erschienen am 24.10.2026. Verfasst von Shuyun Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Reproductive and Developmental Biology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Trian…. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
The tamoxifen-inducible PgriCreERT2 mouse model enables temporal Cre recombination in progesterone receptor (Pgr)-expressing reproductive tissues. However, it remains unclear whether the PgriCreERT2 model can be safely activated during pregnancy, as tamoxifen exposure in pregnant mice can adversely affect pregnancy outcomes. Here, we established a 4-hydroxytamoxifen dosing strategy for inducing Cre recombination after implantation using the PgriCreERT2 model. Pregnant females carrying PgriCreERT2 and a Cre-dependent Rosa26Sun1 reporter were administered a single dose of 4-hydroxytamoxifen at gestational day 8.5. Dose-dependent effects on pregnancy and reporter recombination were evaluated using gross morphology, immunofluorescence, histology, placental and fetal measurements, gestation length, litter size, and resorption rate. A dose of 37.5 mg/kg produced robust SUN1 reporter activation in postimplantation uterine tissues while avoiding the overt adverse effects observed at the higher dose tested. Reporter-positive cells were detected predominantly in the uterus. Placental morphology, steroid hormone receptor (PGR and estrogen receptor alpha (ERα/ESR1)), placental development, and vascularization were preserved following treatment. These findings establish a practical 4-hydroxytamoxifen induction regimen for temporally controlled recombination in the PgriCreERT2 model during postimplantation pregnancy and provide a methodological framework for studying uterine cell function during decidualization, placentation, and maternal–fetal development while reducing pregnancy-related confounding effects.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Reproductive and Developmental Biology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA.
ORCID-Profile: Shuyun Li, Francesco J DeMayo
Zitieren
APA
Li, S., & DeMayo, F. J. (2026). Genetic engineering in the post implantation uterus using a 4-hydroxytamoxifen regulated Cre recombination. Biology of Reproduction. https://doi.org/10.1093/biolre/ioag239
Vancouver
Li S, DeMayo FJ. Genetic engineering in the post implantation uterus using a 4-hydroxytamoxifen regulated Cre recombination. Biology of Reproduction. 2026. doi:10.1093/biolre/ioag239
BibTeX
@article{Li2026,
author = {Li, Shuyun and DeMayo, Francesco J},
title = {Genetic engineering in the post implantation uterus using a 4-hydroxytamoxifen regulated Cre recombination},
journal = {Biology of Reproduction},
year = {2026},
doi = {10.1093/biolre/ioag239}
}
EUVIMED